Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Operating Expenses | 1,871 | 2,002 | 2,449 | 5,380 | 3,730 |
| Operating Income | -1,871 | -2,002 | -2,449 | -5,380 | -3,730 |
| Other Income | 278 | 172 | -190 | 30 | -4 |
| Pre-tax Income | -1,593 | -1,830 | -2,639 | -5,350 | -3,734 |
| Net Income Continuous | -1,593 | -1,830 | -2,639 | -5,350 | -3,734 |
| Net Income | $-1,593 | $-1,830 | $-2,639 | $-5,350 | $-3,734 |
| EPS Basic Total Ops | -11.40 | -12.97 | -18.49 | -38.30 | -27.01 |
| EPS Basic Continuous Ops | -11.38 | -12.98 | -18.83 | -38.25 | -26.80 |
| EPS Diluted Total Ops | -11.40 | -12.97 | -18.49 | -38.30 | -27.01 |
| EPS Diluted Continuous Ops | -11.38 | -12.98 | -18.83 | -38.25 | -26.80 |
| EBITDA(a) | $-1,681 | $-2,160 | $-2,499 | $-5,350 | $-3,717 |